Injectable Biologic Therapies for Intervertebral Disc
Featuring: Zorica Buser, PhD, Mark Erwin, DC, PhD
Disclosures:
Buser, Zorica: Consulting: AOSpine (B), Xenco Medical (B); Research Support (Investigator Salary): SeaSpine (F, Paid directly to institution/employer); Research Support (Staff and/or materials): SeaSpine (F, Paid directly to institution/employer); Trips/Travel: AOSpine (Travel Expense Reimbursement).
Erwin, William Mark: Board of Directors: Notogen (Stock Ownership disclosed); Grants: Skoll Family Trust (G,Paid directly to institution/employer); Research Support (Investigator Salary): Canadian Chiropractic Research Foundation (D); Research Support (Staff and/or materials): Skoll Family Trust (F, Paid directly to institution/employer); Scientific Advisory Board: Notogen (Stock Ownership dislcosed); Stock Ownership (including options, warrants): Notogen Inc (33%).
Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
Create your
podcast in
minutes
It is Free